Spots Global Cancer Trial Database for A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors
Official Title: A Phase II Trial of LEE011 in Combination With Everolimus in the Treatment of Advanced Well Differentiated Neuroendocrine Tumors of Foregut Origin
Study ID: NCT03070301
Conditions
Study Description
Brief Summary: The purpose of this study is to test any good and bad effects of the combination of LEE011 with everolimus on the participant and the cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Md Anderson Cancer Center, Houston, Texas, United States
Contact Details
Name: Diane Reidy-Lagunes, MD, MS
Affiliation: Memorial Sloan Kettering Cancer Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
